A secreted 25 kDa protein naturally expressed in airway epithelial tissues exhibits potent antimicrobial activity against bacteria and viruses, while also modulating immune responses and safeguarding ion channels from proteolytic cleavage. Its ability to regulate airway surface liquid and reduce biofilm formation has been demonstrated in preclinical models. Researchers have developed recombinant protein forms, specific antibodies, and ELISA assays to detect and quantify the protein, and have employed transgenic mice to assess its in vivo efficacy. These features collectively suggest significant utility in enhancing lung innate defenses against respiratory pathogens.
Description
This approach is uniquely differentiated by its dual mechanism of direct microbial killing and immunomodulation, traits not commonly observed in conventional therapies for respiratory infections. Its natural upregulation in response to microbial or cytokine stimulation further underscores its role in maintaining respiratory homeostasis. The comprehensive validation across various experimental models, along with its similarity to bactericidal/permeability-increasing proteins, positions the technology as a promising candidate for novel diagnostic and therapeutic applications in respiratory medicine.
Applications
- Respiratory infection treatment
- Protein biomarker diagnostics
- Recombinant therapeutic development
- Antimicrobial biofilm prevention
Advantages
- Direct antimicrobial activity against both bacteria and viruses.
- Enhancement of innate lung defenses through immunomodulatory functions.
- Protection of airway surface liquid by preventing proteolytic cleavage of key ion channels.
- Reduction of biofilm formation, leading to improved survival in respiratory infections.
- Dual diagnostic and therapeutic potential supported by recombinant proteins, specific antibodies, ELISA assays, and transgenic animal models.
IP Status
Research Tool
